<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-11-24" updated="2019-12-02">
  <drugbank-id primary="true">DB09333</drugbank-id>
  <name>Iopodic acid</name>
  <description>Iopodic acid, also known by the name of ipodate, is classified as a cholecystographic agent formed by a weak organic acid that contains a tri-iodinated benzene ring with iodine at positions 2, 4 and 6.[A32080] Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was developed and filed to the FDA by the company BRACCO. This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada. On September 22, 1981, ipodate was submitted again by the company Schering AG but it is currently under an inactive status.[L1082]</description>
  <cas-number>5587-89-3</cas-number>
  <unii>F604ZKI910</unii>
  <average-mass>597.961</average-mass>
  <monoisotopic-mass>597.81111</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
    <group>withdrawn</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A32080</ref-id>
        <pubmed-id>20641974</pubmed-id>
        <citation>Cheng KT: Sodium-2-[(3-butanoylamino-2,4,6-triiodo-phenyl)methyl]butanoate .</citation>
      </article>
      <article>
        <ref-id>A32085</ref-id>
        <pubmed-id>1687043</pubmed-id>
        <citation>Martino E, Balzano S, Bartalena L, Loviselli A, Sica V, Petrini L, Grasso L, Piga M, Braverman LE: Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism. J Endocrinol Invest. 1991 Nov;14(10):847-51. doi: 10.1007/BF03347940.</citation>
      </article>
      <article>
        <ref-id>A32086</ref-id>
        <pubmed-id>7608275</pubmed-id>
        <citation>Chopra IJ, van Herle AJ, Korenman SG, Viosca S, Younai S: Use of sodium ipodate in management of hyperthyroidism in subacute thyroiditis. J Clin Endocrinol Metab. 1995 Jul;80(7):2178-80. doi: 10.1210/jcem.80.7.7608275.</citation>
      </article>
      <article>
        <ref-id>A32087</ref-id>
        <pubmed-id>11344170</pubmed-id>
        <citation>Braga M, Cooper DS: Clinical review 129: Oral cholecystographic agents and the thyroid. J Clin Endocrinol Metab. 2001 May;86(5):1853-60. doi: 10.1210/jcem.86.5.7484.</citation>
      </article>
    </articles>
    <textbooks>
      <textbook>
        <ref-id>T85</ref-id>
        <isbn/>
        <citation>Woo T.M. and Robinson M. (2016). Pharmacotherapeutics for advanced practice nurse prescribers (4th ed.). Davis Company.</citation>
      </textbook>
      <textbook>
        <ref-id>T125</ref-id>
        <isbn/>
        <citation>Swanson D., et al.  (1990). Pharmaceuticals in medical imaging. McGraw-Hill Professional.</citation>
      </textbook>
    </textbooks>
    <links>
      <link>
        <ref-id>L1082</ref-id>
        <title>FDA Submission</title>
        <url>https://www.fda.gov/downloads/drugs/developmentapprovalprocess/formssubmissionrequirements/drugmasterfilesdmfs/ucm370723.txt</url>
      </link>
      <link>
        <ref-id>L1587</ref-id>
        <title>Up to date</title>
        <url>https://www.uptodate.com/contents/iodinated-radiocontrast-agents-in-the-treatment-of-hyperthyroidism</url>
      </link>
      <link>
        <ref-id>L1589</ref-id>
        <title>Radiologyinfo</title>
        <url>https://www.radiologyinfo.org/en/info.cfm?pg=abdominrad</url>
      </link>
      <link>
        <ref-id>L1590</ref-id>
        <title>Endocrinology association</title>
        <url>https://www.thyroid.org/hyperthyroidism/</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Iopodic acid is available as a cholecystographic agent. This denomination indicates the iopodic acid is a radiopaque substance that can be used to visualize the gallbladder and biliary channels in abdominal X-ray.[L1587, A32087] An abdominal X-ray uses a minimal amount of ionizing radiation to produce pictures of the inside of the abdominal cavity. It is commonly used to evaluate the stomach, liver, intestines, and spleen.[L1589]&#13;
&#13;
Iopodic acid has also been indicated for the treatment of hyperthyroidism such as Graves disease.[A32085, A32086] Hyperthyroidism refers to any condition where there is too much thyroid hormone produced in the body (overactive thyroid). When the overactivity involves the entire thyroid gland, it is known as Grave's disease.[L1590]</indication>
  <pharmacodynamics>The thyroid effects of iopodic acid are related to the blocking of the more potent form of the thyroid hormone. It also blocks thyroid hormone release and it can interfere with its synthesis in some patients. The effects of iopopdic acid on some diseases, such as Graves disease, have been shown not to be as effective and to present a relapse after discontinuation.[A32085, A32086] The effects of iopodic acid on thyroid has been proven to produce an inactivation of approximately 80% of the type II deiodinase in pituitary and cerebral cortex.[A32087]</pharmacodynamics>
  <mechanism-of-action>For cholecystography, iopodic acid blocks the X-rays as they pass through the body which allows delineating the body structures that do not contain this compound.[T125]&#13;
&#13;
The use of iopodic acid in hyperthyroidism is related to the inhibition of 5'-monodeiodinase type I and II; this will later impair the extrathyroidal conversion of thyroxine (T4) to triiodothyronine (T3).[A32085, A32086] </mechanism-of-action>
  <toxicity>Iopodic acid is cathegorized as one of the top 10 linked to skin reactions.[T85]</toxicity>
  <metabolism>The absence of a substituent at position 5 facilitates for preferential hepatocyte uptake. Once taken in the liver, the metabolism is mainly performed by glucuronide conjugation in the same pathway as bilirubin.[A32080]</metabolism>
  <absorption>The lipophilicity of ipodate is sufficient for passage through the gastrointestinal mucosa.[A32080] After ingestion, iopodic acid is promptly absorbed by passive diffusion in the small intestinal mucosa. The presence of bile salts in the duodenum is essential for its diffusion through the intestine wall and a high-fat diet is important in order to increase the absorption effectivity. The maximum effect is showed to be attained 5 hours after the initial dosage and the effect were retained for more than 60 hours.[A32087]</absorption>
  <half-life/>
  <protein-binding>The absence of a substituent at position 5 allows the compound to bind to serum albumin.[A32080] This is the reason why immediately after absorption, iopanoic acid enters the bloodstream it binds to albumin and it is transported to the liver.[A32087]</protein-binding>
  <route-of-elimination>The metabolism products of ipodate are readily excreted into the bile, follow the bile flow to fill up the gallbladder and then excreted by the biliary system in the feces.[A32080] This mode of excretion accounts for 65% of the eliminated dose whereas the kidneys are responsible for the remaining 35% of the elimination.[A32087]</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as phenylpropanoic acids. These are compounds with a structure containing a benzene ring conjugated to a propanoic acid.</description>
    <direct-parent>Phenylpropanoic acids</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Phenylpropanoids and polyketides</superclass>
    <class>Phenylpropanoic acids</class>
    <subclass/>
    <alternative-parent>Aryl iodides</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxamidines</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Formamidines</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Iodobenzenes</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organoiodides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Propargyl-type 1,3-dipolar organic compounds</alternative-parent>
    <substituent>3-phenylpropanoic-acid</substituent>
    <substituent>Amidine</substituent>
    <substituent>Aromatic homomonocyclic compound</substituent>
    <substituent>Aryl halide</substituent>
    <substituent>Aryl iodide</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid amidine</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Formamidine</substituent>
    <substituent>Halobenzene</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Iodobenzene</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>Organic 1,3-dipolar compound</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organoiodide</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Propargyl-type 1,3-dipolar organic compound</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001319</drugbank-id>
      <name>Ipodate calcium</name>
      <unii>50S7W5M9ZZ</unii>
      <cas-number>1151-11-7</cas-number>
      <inchikey>HVZGHKKROPCBDE-UHFFFAOYSA-L</inchikey>
      <average-mass>1233.985</average-mass>
      <monoisotopic-mass>1233.56917</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001318</drugbank-id>
      <name>Ipodate sodium</name>
      <unii>F316LLW9WW</unii>
      <cas-number>1221-56-3</cas-number>
      <inchikey>ZFHZUGUCWJVEQC-UHFFFAOYSA-M</inchikey>
      <average-mass>619.943</average-mass>
      <monoisotopic-mass>619.79306</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">Ipodate</synonym>
  </synonyms>
  <products>
    <product>
      <name>Oragrafin Sodium 0.5gm</name>
      <labeller>Bracco Imaging S.P.A.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01973746</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1969-12-31</started-marketing-on>
      <ended-marketing-on>1999-07-30</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Oragrafin Sodium 0.5gm</name>
      <ingredients>Iopodic acid</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Benzene Derivatives</category>
      <mesh-id>D001555</mesh-id>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Contrast Media</category>
      <mesh-id>D003287</mesh-id>
    </category>
    <category>
      <category>Diagnostic Uses of Chemicals</category>
      <mesh-id>D064907</mesh-id>
    </category>
    <category>
      <category>Hydrocarbons, Halogenated</category>
      <mesh-id>D006846</mesh-id>
    </category>
    <category>
      <category>Hydrocarbons, Iodinated</category>
      <mesh-id>D006847</mesh-id>
    </category>
    <category>
      <category>Iodobenzenes</category>
      <mesh-id>D007462</mesh-id>
    </category>
    <category>
      <category>Watersoluble, Hepatotropic X-Ray Contrast Media</category>
      <mesh-id/>
    </category>
    <category>
      <category>X-Ray Contrast Media, Iodinated</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="V08AC08">
      <level code="V08AC">Watersoluble, hepatotropic X-ray contrast media</level>
      <level code="V08A">X-RAY CONTRAST MEDIA, IODINATED</level>
      <level code="V08">CONTRAST MEDIA</level>
      <level code="V">VARIOUS</level>
    </atc-code>
    <atc-code code="V08AC10">
      <level code="V08AC">Watersoluble, hepatotropic X-ray contrast media</level>
      <level code="V08A">X-RAY CONTRAST MEDIA, IODINATED</level>
      <level code="V08">CONTRAST MEDIA</level>
      <level code="V">VARIOUS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB09333.pdf?1520546002</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.59</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.9</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>8.19e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>3-(3-{[(dimethylamino)methylidene]amino}-2,4,6-triiodophenyl)propanoic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>ipodate sodium</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>597.961</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>597.81111</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CN(C)C=NC1=C(I)C=C(I)C(CCC(O)=O)=C1I</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C12H13I3N2O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C12H13I3N2O2/c1-17(2)6-16-12-9(14)5-8(13)7(11(12)15)3-4-10(18)19/h5-6H,3-4H2,1-2H3,(H,18,19)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>YQNFBOJPTAXAKV-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>52.9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>104.91</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>40.23</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>1.99</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>4.16</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Insoluble</value>
      <source>Cheng K. (2005). Molecular imaging and contrast agent database.</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>168-169ºC</value>
      <source>ChemSrc</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>579.8ºC at 760 mmHg</value>
      <source>ChemSrc</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.73</value>
      <source>ChemSrc</source>
    </property>
    <property>
      <kind>pKa</kind>
      <value>4.8</value>
      <source>Elks. The dictionary of Drugs. (1990)</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>4144</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5241</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>310265212</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>20473670</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL3306201</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0009333</id>
      <name>Thyroxine 5-deiodinase</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A32085</ref-id>
            <pubmed-id>1687043</pubmed-id>
            <citation>Martino E, Balzano S, Bartalena L, Loviselli A, Sica V, Petrini L, Grasso L, Piga M, Braverman LE: Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism. J Endocrinol Invest. 1991 Nov;14(10):847-51. doi: 10.1007/BF03347940.</citation>
          </article>
          <article>
            <ref-id>A32086</ref-id>
            <pubmed-id>7608275</pubmed-id>
            <citation>Chopra IJ, van Herle AJ, Korenman SG, Viosca S, Younai S: Use of sodium ipodate in management of hyperthyroidism in subacute thyroiditis. J Clin Endocrinol Metab. 1995 Jul;80(7):2178-80. doi: 10.1210/jcem.80.7.7608275.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P55073" source="Swiss-Prot">
        <name>Thyroxine 5-deiodinase</name>
        <general-function>Responsible for the deiodination of T4 (3,5,3',5'-tetraiodothyronine) into RT3 (3,3',5'-triiodothyronine) and of T3 (3,5,3'-triiodothyronine) into T2 (3,3'-diiodothyronine). RT3 and T2 are inactive metabolites. May play a role in preventing premature exposure of developing fetal tissues to adult levels of thyroid hormones. Can regulate circulating fetal thyroid hormone concentrations throughout gestation. Essential role for regulation of thyroid hormone inactivation during embryological development.</general-function>
        <specific-function>Thyroxine 5'-deiodinase activity</specific-function>
        <gene-name>DIO3</gene-name>
        <locus>14q32.31</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>45-67</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>33947.175</molecular-weight>
        <chromosome-location>14</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2885</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P55073</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>IOD3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.21.99.3</synonym>
          <synonym>5DIII</synonym>
          <synonym>DIOIII</synonym>
          <synonym>ITDI3</synonym>
          <synonym>TXDI3</synonym>
          <synonym>Type 3 DI</synonym>
          <synonym>Type III iodothyronine deiodinase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0051588|Thyroxine 5-deiodinase
MPRQATSRLVVGEGEGSQGASGPAATMLRSLLLHSLRLCAQTASCLVLFPRFLGTAFMLW
LLDFLCIRKHFLGRRRRGQPEPEVELNSEGEEVPPDDPPICVSDDNRLCTLASLKAVWHG
QKLDFFKQAHEGGPAPNSEVVLPDGFQSQHILDYAQGNRPLVLNFGSCTUPPFMARMSAF
QRLVTKYQRDVDFLIIYIEEAHPSDGWVTTDSPYIIPQHRSLEDRVSAARVLQQGAPGCA
LVLDTMANSSSSAYGAYFERLYVIQSGTIMYQGGRGPDGYQVSELRTWLERYDEQLHGAR
PRRV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0051589|Thyroxine 5-deiodinase (DIO3)
ATGCCTCGCCAGGCCACGTCGCGGTTGGTGGTCGGAGAGGGCGAGGGGTCCCAGGGGGCT
TCGGGGCCTGCAGCCACCATGCTCCGCTCCCTGCTGCTTCACTCCTTGAGGCTCTGCGCC
CAGACCGCCTCGTGCCTCGTGCTCTTCCCGCGCTTCCTCGGCACGGCCTTCATGCTCTGG
CTTCTCGATTTCTTGTGTATCCGCAAGCATTTCCTGGGCCGCCGCCGCCGGGGGCAGCCC
GAGCCCGAAGTGGAGCTCAACAGTGAAGGCGAGGAGGTGCCTCCCGATGACCCGCCCATC
TGCGTGTCCGACGACAACCGCCTGTGCACCCTGGCGTCGCTCAAGGCGGTGTGGCATGGC
CAGAAGTTGGATTTCTTCAAGCAGGCGCACGAGGGCGGTCCGGCGCCCAACTCCGAGGTG
GTTCTGCCCGACGGCTTCCAGAGCCAGCACATCCTCGACTACGCGCAAGGGAACCGCCCG
CTGGTTCTCAATTTCGGCAGCTGCACCTGACCACCGTTCATGGCGCGCATGAGCGCCTTC
CAGCGCCTGGTCACTAAGTACCAGCGCGACGTCGACTTCCTCATCATCTACATCGAGGAA
GCGCACCCCTCCGACGGCTGGGTCACCACGGACTCTCCCTACATCATCCCACAGCACCGG
AGCCTGGAGGACCGGGTCAGCGCAGCGAGGGTACTGCAGCAAGGTGCACCCGGCTGCGCT
CTGGTCCTCGACACCATGGCCAACTCCAGCAGCTCGGCCTATGGCGCCTACTTCGAGCGT
CTCTATGTCATCCAGAGTGGCACTATTATGTACCAGGGCGGCCGTGGCCCCGACGGCTAC
CAGGTCTCTGAGCTGCGCACTTGGTTGGAACGCTATGATGAGCAACTGCACGGCGCTCGG
CCCCGGAGGGTGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00837</identifier>
            <name>T4_deiodinase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endosome membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>thyroxine 5-deiodinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>thyroxine 5'-deiodinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hormone biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinal cone cell development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thyroid hormone catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thyroid hormone generation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers>
    <carrier position="2">
      <id>BE0000530</id>
      <name>Serum albumin</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A32080</ref-id>
            <pubmed-id>20641974</pubmed-id>
            <citation>Cheng KT: Sodium-2-[(3-butanoylamino-2,4,6-triiodo-phenyl)methyl]butanoate .</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P02768" source="Swiss-Prot">
        <name>Serum albumin</name>
        <general-function>Toxic substance binding</general-function>
        <specific-function>Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.</specific-function>
        <gene-name>ALB</gene-name>
        <locus>4q11-q13</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>6.21</theoretical-pi>
        <molecular-weight>69365.94</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:399</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ALB</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>V00494</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>28590</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P02768</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ALBU_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Serum albumin precursor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001058|Serum albumin
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF
EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP
ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV
ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK
ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR
RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE
QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV
LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL
SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV
AASQAALGL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010372|Serum albumin (ALB)
ATGAAGTGGGTAACCTTTATTTCCCTTCTTTTTCTCTTTAGCTCGGCTTATTCCAGGGGT
GTGTTTCGTCGAGATGCACACAAGAGTGAGGTTGCTCATCGGTTTAAAGATTTGGGAGAA
GAAAATTTCAAAGCCTTGGTGTTGATTGCCTTTGCTCAGTATCTTCAGCAGTGTCCATTT
GAAGATCATGTAAAATTAGTGAATGAAGTAACTGAATTTGCAAAAACATGTGTTGCTGAT
GAGTCAGCTGAAAATTGTGACAAATCACTTCATACCCTTTTTGGAGACAAATTATGCACA
GTTGCAACTCTTCGTGAAACCTATGGTGAAATGGCTGACTGCTGTGCAAAACAAGAACCT
GAGAGAAATGAATGCTTCTTGCAACACAAAGATGACAACCCAAACCTCCCCCGATTGGTG
AGACCAGAGGTTGATGTGATGTGCACTGCTTTTCATGACAATGAAGAGACATTTTTGAAA
AAATACTTATATGAAATTGCCAGAAGACATCCTTACTTTTATGCCCCGGAACTCCTTTTC
TTTGCTAAAAGGTATAAAGCTGCTTTTACAGAATGTTGCCAAGCTGCTGATAAAGCTGCC
TGCCTGTTGCCAAAGCTCGATGAACTTCGGGATGAAGGGAAGGCTTCGTCTGCCAAACAG
AGACTCAAGTGTGCCAGTCTCCAAAAATTTGGAGAAAGAGCTTTCAAAGCATGGGCAGTA
GCTCGCCTGAGCCAGAGATTTCCCAAAGCTGAGTTTGCAGAAGTTTCCAAGTTAGTGACA
GATCTTACCAAAGTCCACACGGAATGCTGCCATGGAGATCTGCTTGAATGTGCTGATGAC
AGGGCGGACCTTGCCAAGTATATCTGTGAAAATCAAGATTCGATCTCCAGTAAACTGAAG
GAATGCTGTGAAAAACCTCTGTTGGAAAAATCCCACTGCATTGCCGAAGTGGAAAATGAT
GAGATGCCTGCTGACTTGCCTTCATTAGCTGCTGATTTTGTTGAAAGTAAGGATGTTTGC
AAAAACTATGCTGAGGCAAAGGATGTCTTCCTGGGCATGTTTTTGTATGAATATGCAAGA
AGGCATCCTGATTACTCTGTCGTGCTGCTGCTGAGACTTGCCAAGACATATGAAACCACT
CTAGAGAAGTGCTGTGCCGCTGCAGATCCTCATGAATGCTATGCCAAAGTGTTCGATGAA
TTTAAACCTCTTGTGGAAGAGCCTCAGAATTTAATCAAACAAAATTGTGAGCTTTTTGAG
CAGCTTGGAGAGTACAAATTCCAGAATGCGCTATTAGTTCGTTACACCAAGAAAGTACCC
CAAGTGTCAACTCCAACTCTTGTAGAGGTCTCAAGAAACCTAGGAAAAGTGGGCAGCAAA
TGTTGTAAACATCCTGAAGCAAAAAGAATGCCCTGTGCAGAAGACTATCTATCCGTGGTC
CTGAACCAGTTATGTGTGTTGCATGAGAAAACGCCAGTAAGTGACAGAGTCACCAAATGC
TGCACAGAATCCTTGGTGAACAGGCGACCATGCTTTTCAGCTCTGGAAGTCGATGAAACA
TACGTTCCCAAAGAGTTTAATGCTGAAACATTCACCTTCCATGCAGATATATGCACACTT
TCTGAGAAGGAGAGACAAATCAAGAAACAAACTGCACTTGTTGAGCTCGTGAAACACAAG
CCCAAGGCAACAAAAGAGCAACTGAAAGCTGTTATGGATGATTTCGCAGCTTTTGTAGAG
AAGTGCTGCAAGGCTGACGATAAGGAGACCTGCTTTGCCGAGGAGGGTAAAAAACTTGTT
GCTGCAAGTCAAGCTGCCTTAGGCTTATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00273</identifier>
            <name>Serum_albumin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>myelin sheath</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet alpha granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>antioxidant activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chaperone binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>copper ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>fatty acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>pyridoxal phosphate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>toxic substance binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to starvation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hemolysis by symbiont of host erythrocytes</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipoprotein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maintenance of mitochondrion location</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of programmed cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </carrier>
  </carriers>
  <transporters/>
</drug>